Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis
Authors
Keywords
-
Journal
CEPHALALGIA
Volume -, Issue -, Pages 033310242198960
Publisher
SAGE Publications
Online
2021-02-13
DOI
10.1177/0333102421989601
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
- (2020) Messoud Ashina et al. CEPHALALGIA
- Efficacy and safety of eptinezumab in patients with chronic migraine
- (2020) Richard B. Lipton et al. NEUROLOGY
- Effects of Anti-Calcitonin Gene-Related Peptide for Migraines: A Systematic Review with Meta-Analysis of Randomized Clinical Trials
- (2019) I-Hsin Huang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
- (2018) Vladimir Skljarevski et al. CEPHALALGIA
- ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
- (2018) David W Dodick et al. CEPHALALGIA
- Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine
- (2018) David W. Dodick et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Migraine is first cause of disability in under 50s: will health politicians now take notice?
- (2018) Timothy J. Steiner et al. JOURNAL OF HEADACHE AND PAIN
- Evaluation of Galcanezumab for the Prevention of Episodic Migraine
- (2018) Virginia L. Stauffer et al. JAMA Neurology
- Benefit-risk assessment of erenumab and current migraine prophylactic treatments using the likelihood of being helped or harmed
- (2018) Pamela Vo et al. CEPHALALGIA
- Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation
- (2018) Lars Bendtsen et al. JOURNAL OF HEADACHE AND PAIN
- Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
- (2018) Lars Jacob Stovner et al. LANCET NEUROLOGY
- Galcanezumab in chronic migraine
- (2018) Holland C. Detke et al. NEUROLOGY
- Likelihood of Being Helped or Harmed as a Measure of Clinical Outcomes in Psychopharmacology
- (2017) Chittaranjan Andrade JOURNAL OF CLINICAL PSYCHIATRY
- Patients’ preferences for headache acute and preventive treatment
- (2017) Dimos D. Mitsikostas et al. JOURNAL OF HEADACHE AND PAIN
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Stewart Tepper et al. LANCET NEUROLOGY
- Fremanezumab for the Preventive Treatment of Chronic Migraine
- (2017) Stephen D. Silberstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Controlled Trial of Erenumab for Episodic Migraine
- (2017) Peter J. Goadsby et al. NEW ENGLAND JOURNAL OF MEDICINE
- Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis
- (2016) Zsolt Hepp et al. CEPHALALGIA
- New players in the preventive treatment of migraine
- (2015) Dimos D. Mitsikostas et al. BMC Medicine
- Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine
- (2014) H.-C. Diener et al. EUROPEAN JOURNAL OF NEUROLOGY
- When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed
- (2013) L. Citrome et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Table 1
- (2012) S.D. Silberstein et al. NEUROLOGY
- OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56-Week PREEMPT Clinical Program
- (2011) Sheena K. Aurora et al. HEADACHE
- Topiramate intervention to prevent transformation of episodic migraine: The topiramate INTREPID study
- (2010) Richard B Lipton et al. CEPHALALGIA
- OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
- (2010) SK Aurora et al. CEPHALALGIA
- OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
- (2010) HC Diener et al. CEPHALALGIA
- OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program
- (2010) David W. Dodick et al. HEADACHE
- EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force
- (2009) S. Evers et al. EUROPEAN JOURNAL OF NEUROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started